Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.41 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.40 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.38 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.38 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.38 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.38 |
| ▸ | CTSB | P07858 | 1/20 | 0.38 |
| ▸ | LOX | P28300 | 1/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.37 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.37 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.37 |
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30569427 | 1.00 | CYP2D6 (0.45) | CYP2D6MEN1CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL23665806 | 0.83 | CYP2D6 (0.43) | CYP2D6MEN1CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL17848762 | 0.83 | MEN1 (0.42) | CYP2D6MEN1CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL2024322 | 0.82 | CTSB (0.53) | CYP2D6MEN1CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL4434908 | 0.82 | CYP2D6 (0.56) | CYP2D6MEN1KMT2ACA12APOBEC3G | |
| SCHEMBL18978745 | 0.82 | CYP2D6 (0.36) | CYP2D6MEN1CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL3298438 | 0.82 | PDCD1 (0.47) | CYP2D6MEN1CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL19617799 | 0.81 | PSIP1 (0.45) | CYP2D6CYP1A2CYP3A4CYP2C19CA12 | |
| SCHEMBL5663968 | 0.80 | ADRA1D (0.41) | CYP2D6MEN1CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL23665755 | 0.80 | CYP2D6 (0.41) | CYP2D6MEN1CYP1A2CYP3A4CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111205452-A | Phenolphthalein type high-dielectric polyarylether resin with side chain containing methylsulfonyl and preparation method thereof | 长安大学 | 2020-05-29 | — | — | CN | claimed |
| CN-111187406-A | Bisphenol acid type polyarylether dielectric material with side chain containing methylsulfonyl and preparation method thereof | 长安大学 | 2020-05-22 | — | — | CN | claimed |
| CN-111205452-B | Phenolphthalein type high-dielectric polyarylether resin with side chain containing methylsulfonyl and preparation method thereof | 长安大学 | 2023-07-04 | — | — | CN | disclosed |
| CN-111205452-A | Phenolphthalein type high-dielectric polyarylether resin with side chain containing methylsulfonyl and preparation method thereof | 长安大学 | 2020-05-29 | — | — | CN | disclosed |
| CN-111187406-A | Bisphenol acid type polyarylether dielectric material with side chain containing methylsulfonyl and preparation method thereof | 长安大学 | 2020-05-22 | — | — | CN | disclosed |
| CN-106257976-A | Human plasma kallikrein inhibitors | 拜奥克里斯特制药公司 | 2016-12-28 | — | — | CN | disclosed |
| US-8916593-B2 | Alkoxy-substituted 2-aminopyridines as ALK inhibitors | PFIZER INC. (US) | 2014-12-23 | — | — | US | disclosed |
| US-8580780-B2 | 6 substituted 2, 3,4,5 tetrahydro-1H-benzo[d]azepines as 5-HT2C receptor agonist | ELI LILLY AND COMPANY (US) | 2013-11-12 | — | — | US | disclosed |
| US-8580780-B2 | 6 substituted 2, 3,4,5 tetrahydro-1H-benzo[d]azepines as 5-HT2C receptor agonist | ELI LILLY AND COMPANY (US) | 2013-11-12 | — | — | US | disclosed |
| US-8580780-B2 | 6 substituted 2, 3,4,5 tetrahydro-1H-benzo[d]azepines as 5-HT2C receptor agonist | ELI LILLY AND COMPANY (US) | 2013-11-12 | — | — | US | disclosed |
| US-20130196952-A1 | HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF DISEASES | PFIZER INC. (US) | 2013-08-01 | — | — | US | disclosed |
| EP-1720836-A1 | 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO [D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2006-11-15 | — | — | EP | disclosed |
| WO-2005082859-A1 | 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2005-09-09 | — | — | WO | disclosed |
| EP-0882715-B1 | NOVEL N-(UNSUBSTITUTED OR SUBSTITUTED)-4-SUBSTITUTED-6-(UNSUBSTITUTED OR SUBSTITUTED)PHENOXY-2-PYRIDINECARBOXAMIDES OR THIOCARBOXAMIDES, PROCESSES FOR PRODUCING THE SAME, AND HERBICIDES | KUREHA CHEMICAL IND CO LTD (JP) | 2003-04-23 | — | — | EP | disclosed |
| EP-1165082-A4 | INHIBITORS OF PRENYL-PROTEIN TRANSFERASE | MERCK & CO INC (US) | 2002-06-12 | — | — | EP | disclosed |
| US-6358956-B1 | IMIDAZOLYLALKYL-1-PIPERAZINE DERIVATIVES; FARNESYL-PROTEIN AND GERANYLGERANYL TRANSFERASE INHIBITORS; ANTICARCINOGENIC AGENTS | MERCK & CO., INC. | 2002-03-19 | — | — | US | disclosed |
| US-6339045-B1 | CAN BE USED IN A SMALL AMOUNT, SHOWING A GOOD SELECTIVITY BETWEEN CROP AND WEED, AND CAUSING NO PHYTOTOXICITY | KUREHA KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 2002-01-15 | — | — | US | disclosed |
| EP-1165082-A1 | INHIBITORS OF PRENYL-PROTEIN TRANSFERASE | Merck & Co., Inc. (US) | 2002-01-02 | — | — | EP | disclosed |
| WO-2000051611-A1 | INHIBITORS OF PRENYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 2000-09-08 | — | — | WO | disclosed |
| EP-0882715-A1 | NOVEL N-(UNSUBSTITUTED OR SUBSTITUTED)-4-SUBSTITUTED-6-(UNSUBSTITUTED OR SUBSTITUTED)PHENOXY-2-PYRIDINECARBOXAMIDES OR THIOCARBOXAMIDES, PROCESSES FOR PRODUCING THE SAME, AND HERBICIDES | KUREHA KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1998-12-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130196952-A1 | HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF DISEASES | ALK, ETV6, ACVR1 | CYP2D6 897/4885MEN1 441/4885CYP1A2 369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.